News

Bioptix Announces Executive Leadership Change

Bioptix, Inc. announced that its board of directors has appointed Michael M. Beeghley as chief executive officer effective as of April 6, 2017. Mr. Beeghley succeeds Steve Lundy, who resigned as of April 6, 2017 from his role as president and chief executive officer, and member of the board of directors. Mr. Beeghley will continue in his role as Chairman of the Company’s Board of Directors. Mr. Lundy’s resignation was not the result of any disagreement with the Company.  Read more…


Bioptix Announces Streamlining of Workforce

Bioptix, Inc. (BIOP) (“Bioptix” or the “Company”), announced that on January 14, 2017 the Board of Directors of the Company adopted a plan under which the Company will terminate certain employees associated with the September 2016 acquisition of its subsidiary, Bioptix Diagnostics, Inc.  The Company commenced terminations on January 16, 2017 and terminations are expected to be completed within 30 days.  The Company may pay severance benefits in certain circumstances of up to one month base salary.  The Board determined […]  Read more…


Bioptix Reports Board of Director Changes

Bioptix, Inc. (Nasdaq: BIOP), (the “Company”), announced that Gail Schoettler, Susan Evans and David Welch have resigned from the Company’s Board of Directors. On December 8, 2016, Barry Honig, the beneficial owner of more than ten percent of the outstanding shares of the Company, commenced a legal action in Colorado State court to compel the Company to hold a special meeting of shareholders to, among other items, hold a Director election.  Following commencement of such action, members of the Board of […]  Read more…